Join our daily newsletter At The Bell to receive exclusive market insights
- Real-time software company Vection Technologies (VR1) has signed on its first public hospital to trial its Augmented Reality (AR) healthcare solutions
- The trial will be conducted at the Moscati hospital in Italy and is critical to introduce AR solutions in the Italian healthcare industry
- The trial will focus on AR for endoscopic surgery and electronic medical record system (EMRS) access through wearable devices
- Italy has around 1000 accredited hospitals and 52 per cent of these are public – making it the ideal addressable market
- Vection is currently up a healthy 22.1 per cent and is trading for 8.3 cents
Real-time software company Vection Technologies (VR1) has signed its first public hospital to trial its Augmented Reality (AR) healthcare solutions.
The company has signed an initial trial agreement with AORN S.G. Moscati hospital
(Moscati) and Luiss Libera Università Internazionale degli Studi Sociali Guido Carli (LUISS Business School).
The trial will focus on integrating Vection Technologies’ AR healthcare solutions, based on its FrameS technology infrastructure, within the Moscati hospital.
Vection said this trial is critical to introduce AR solutions in the Italian Model for Risk Management in healthcare.
The trial will focus on AR for endoscopic surgery and electronic medical record system (EMRS) access through wearable devices.
Italy has around 1000 accredited hospitals, of which around 52 per cent are public, which makes the country an ideal test market for the company to introduce its real-time technology.
“We are pleased to have signed this initial trial with Vection Technologies to introduce real-time solutions within the Italian Model for Risk Management in Healthcare,” Associate Dean for Executive Education and Life-Long Learning of Luiss Business School Enzo Peruffo said.
“Augmented reality represents the key to the digital healthcare transformation, potentially transforming healthcare practices across all critical functions, from training to in-practice usage,” he added.
Vection Managing Director, Gianmarco Biagi, said the initial trial represents the lengthy regulatory process which has enabled the company to affirm itself at the forefront of the digital healthcare transformation.
“This agreement represents a key commercial milestone setting the foundations for long-term growth, providing for a strong opportunity for recurring revenue growth during the second half of FY21 and into FY22,” he told the market.
On the market today, Vection is up 22.1 per cent and is trading for 8.3 cents per share at 1:17 pm AEST.
